Since previous studies have shown that chronic inflammatory skin diseases could be connected to psychiatric disorders, Dr Kevin Phan (Liverpool Hospital, Australia) and colleagues were interested in a possible association of HS with psychiatric comorbidities like depression, schizophrenia, or suicidal tendency [4-6]. They also looked at alcohol and substance abuse in this population. The researchers performed a meta-analysis of studies identified by an electronic database search and direct review of articles together with data about cases and controls [4].
Regarding psychiatric diagnoses, the study found significantly elevated risks for HS patient to suffer from schizophrenia (OR 1.66; 95% CI 1.53-1.79; P<0.00001), anxiety (OR 1.71; 95% CI 1.51-1.92; P<0.00001), bipolar disorders (OR 1.96; 95% CI 1.65-2.33; P<0.00001), depression (OR 1.75; 95% CI 1.44-2.13; P<0.00001), and personality disorders (OR 1.50; 95% CI 1.18-1.92; P=0.001). The likelihood of suicide was around 2 times higher (OR 2.08; 95% CI 1.27-3.42; P=0.004) and in about the same order of magnitude as alcohol abuse (OR 1.94; 95% CI 1.43-2.64; P<0.0001). The odds for substance-related disorders were almost 3 times higher (OR 2.84; 95% CI 2.33-3.46; P<0.00001) when HS patients were compared with those without HS.
In view of these results, Dr Phan highlighted the need for dermatologists treating HS patients to consider integrating psychological and psychiatric support to the multidisciplinary management. The authors endorse future studies to evaluate a general screening policy in order to identify suicide risk.
- Menter A. Semin Cutan Med Surg. 2014;33:S54-6.
- Kohorst JJ, et al. J Am Acad Dermatol. 2015;73:S27-35.
- Shlyankevich J,et al. J Am Acad Dermatol 2014;71:1144-1150.
- Phan K, et al. Hidradenitis suppurativa and relationship with psychiatric comorbidities, suicides and substance abuse. P0019, EADV 2020 Virtual Congress, 29-31 Oct.
- Onderdijk AJ, et al. J Eur Acad Dermatol Venereol. 2013;27:473-478.
- Shavit E, et al. J Eur Acad Dermatol Venereol. 2015;29:371-376.
Posted on
Previous Article
« Meaningful sleep improvement with IL-13 inhibition Next Article
Bimekizumab in psoriasis: Up-and-coming »
« Meaningful sleep improvement with IL-13 inhibition Next Article
Bimekizumab in psoriasis: Up-and-coming »
Table of Contents: EADV 2020
Featured articles
Late-Breaking News
Selective IL-23 blocker shows potential in psoriasis treatment
Promising results with nanobody treatment in psoriasis
Light at the end of the tunnel for chronic hand eczema
Epidermolysis bullosa: Novel wound treatment on the horizon
Efficacious non-steroidal topical for psoriasis
Oral JAK 1 inhibitor leads to fast itch relieve and remarkable skin clearance in AD
COVID-19: What Dermatologists Need to Know
Biologic psoriasis treatment and COVID-19 risk: Contradictory results
Much to be learned about COVID-19 and the skin
JAK Inhibitors – A Fascinating Novel Drug Class
JAK inhibitors in AA: re-establishing the immune privilege of hair follicles
JAK1 inhibition successful in hidradenitis suppurativa
Topical JAK inhibition: a novel treatment option for patients with mild-to-moderate AD
Urticaria – What’s new
Chronic inducible urticaria can require some detective work
Chronic spontaneous urticaria: hives, wheals & biomarkers
Ligelizumab for chronic spontaneous urticaria: a new star on the horizon
Infectious Diseases: Novel Developments
Bacterial resistance in skin infections – a challenging threat
Borreliosis: A multifaceted disease
Scabies – A global health challenge
Upcoming Treatments
Meaningful sleep improvement with IL-13 inhibition
Preventing foot odour with zinc oxide coated socks
Baricitinib in AD: Efficacy paired with consistent long-term results
Best of the Posters
Real-world data on brodalumab affirms efficacy and fast onset of action
Heightened risk for psychiatric comorbidities in hidradenitis suppurativa patients
Effects IL-13 blocker improves with longer treatment duration
Related Articles
December 17, 2020
JAK inhibitors in vitiligo
December 17, 2020
Epidermolysis bullosa: Novel wound treatment on the horizon
December 17, 2020
Borreliosis: A multifaceted disease
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com